Toll Free: 18008891064
  • Home
  • About Us
  • Product List
    • ONCOLOGY
      • Cytalux (Pofalacianine)
      • Pylarify (Piflufolastat F18)
      • Truseltiq (Infigratinib)
      • Enhertu (Trastuzumab Deruxtecan)
      • Mektovi (Binimetinib)
      • Braftovi (Encorafenib)
      • Libtayo (Cemiplimab-rwlc)
      • Lorbrena (Lorlatinib)
      • Talzenna (Talazoparib)
      • Balversa (Erdafitinib)
      • Piqray (Alpelisib)
      • Alunbrig (Brigatinib)
      • Jemperli (Dostarlimab-gxly)
      • Tepmetko (Tepotinib)
      • COSELA (Trilaciclib)
      • Fotivda (Tivozanib)
      • Rozlytrek (Entrectinib)
      • Tivdak® (tisotumab vedotin-tftv)
      • Ayvakit (Avapritinib)
      • Tazverik (Tazemetostat)
      • Tukysa (Tucatinib)
      • Pemazyre (Pemigatinib)
      • Trodelvy (Sacituzumab govitecan-hziy)
      • Tabrecta (Capmatinib)
      • Retevmo (Selpercatinib)
      • Zepzelca (Lurbinectedin)
      • Gavreto (Pralsetinib)
      • MARGENZATM (margetuximab-cmkb)
      • Orgovyx (relugolix)
      • DANYELZA (naxitamab-gqgk)
      • ZEJULA (Niraparib)
      • VERZENIO (Abemaciclib)
      • TECENTRIQ (Atezolizumab)
      • NERLYNX (Neratinib)
      • Yervoy
      • CAPRELSA (Vandetnib)
      • CELSENTRI (Maraviroc)
      • CIDOFOVIR (Visitide)
      • IBRANCE (Palbociclib Capsules)
      • COMETRIQ (Cabozantinib)
      • CYRAMZA (Ramucirumab Injection)
      • DABRAFENIB (Tafinlar)
      • ENTEREG (Almiopan Capsule)
      • ERIVEDGE (Vismodegib Tablet)
      • LYNPARZA (Olaparib)
      • Qinlock (Ripretinib)
      • MEKINIST (Trametnib Tablet)
      • Mitotane (Lysodren)
      • NAVELBINE ORAL (Vinorelbine)
      • TEYSUNO (Tegafur)
      • ZELBORAF (Vemurafenib Tablet)
      • Zepzelca (Lurbinectedin)
      • ZYDELIG (Idelalisib)
    • HEMATOLOGY
      • Rezurock (Belumosudil)
      • Empaveli (Pegcetacoplan)
      • Idhifa (Enasidenib)
      • Besponsa (Inotuzumab Ozogamicin)
      • Tibsovo (Ivosidenib)
      • Poteligeo (Mogamulizumab-kpkc)
      • Xospata (Gilteritinib)
      • Asparlas (Calaspargase pegol-mknl)
      • Polivy (Polatuzumab Vedotin-piiqa
      • Reblozyl (Luspatercept–aamt)
      • Ukoniq (Umbralisib)
      • Pepaxto (Melphalan Flufenamide)
      • Zynlonta (Loncastuximab Tesirine-lpyl)
      • Rylaze
      • Exkivity (Mobocertinib)
      • SCEMBLIX®(Asciminib)
      • Besremi (Ropeginterferon alfa-2b-njft)
      • SARCLISA® (isatuximab-irfc)
      • Inqovi (decitabine and cedazuridine)
      • Blenrep (Belantamab Mafodotin-blmf)
      • Monjuvi (Tafasitamab-cxix)
      • TAFINLAR (Dabrafenib)
      • CALQUENCE (Acalabrutinib)
      • MYLOTARG Gemtuzumab
      • Aliqopa(Copanlisib)
      • Brentuximab Vedotin
      • AGRYLIN (Anagrelide Hydrochloride)
      • ATRIANCE (Nelarabine)
      • BLINCYTO (Blinatumomab)
      • ONCASPAR (Pegaspargase)
      • ERWINAZE (Asparaginase Erwinia Chrysanthemi)
      • FOLOTYN (Pralatrexate)
      • TREOSULFAN (Treosulfan)
      • Ponatinib
      • NPLATE (Romiplostim)
      • KYPROLIS (Carfilzomib)
      • MABCAMPATH (Alemtuzumab)
      • VENCLEXTA (Venetoclax)
      • SOLIRIS (eculizumab)
      • SYNRIBO (Omacetaxine Mepesuccinate)
      • ALKERAN (Melphalan)
      • FARYDAK (Panobinostat)
      • BOSULIF (Bosutinib)
      • ELDISINE (Vindesine Sulphate)
      • Ixazomib Citrate
      • TEPADINA (Thiotepa)
      • ZOLINZA (Vorinostat)
    • Nephrology
      • Ultomiris (Ravulizumab)
    • GASTROENTROLOGY
      • VOSEVI (Sofosbuvir, Velpatasvir, And Voxilaprevir)
      • OLYSIO (SIMEPREVIR)
      • SYPRINE (Trientine HCL)
    • NEUROLOGY
      • Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
      • Qelbree (Viloxazine)
      • Lybalvi (Olanzapine and Samidorphan)
      • Aduhelm (aducanumab-avwa)
      • NUEDEXTA (Dextromethorphan Hydrobromide)
      • ILARIS (Canakinumab)
      • GLIOLAN (Aminolevulinic acid hydrochloride)
      • STELARA (Ustekinumab)
      • HUMIRA (Adalimumab)
    • IMMUNOLOGY
      • Ocrevus (Ocrelizumab)
      • Skyrizi (Risankizumab-rzaa)
      • PONVORY®(ponesimod)
      • Zeposia (Ozanimod)
      • SILIQ (Brodalumab)
      • TREMFYA (Guselkumab)
    • RARE DISEASES
      • Nulibry (Fosdenopterin)
      • Welireg (Belzutifan)
      • Xiaflex (Collagenase Clostridium Histolyticum)
      • Mepsevii (Vestronidase alfa-vjbk)
      • Symdeko (Tezacaftor/Ivacaftor & Ivacaftor)
      • Palynziq (Pegvaliase-pqpz)
      • Onpattro (Patisiran)
      • Galafold (Migalastat)
      • Diacomit (Stiripentol)
      • Takhzyro (Lanadelumab)
      • Orfadin (Nitisinone)
      • Trikafta (elexacaftor, tezacaftor and ivacaftor)
      • Spinraza (Nusinersen)
      • Amondys 45 (Casimersen)
      • Voxzogo (Vosoritide)
      • Tepezza (Teprotumumab-trbw)
      • Isturisa (Osilodrostat)
      • Koselugo (Selumetinib)
      • VILTEPSO (Viltolarsen)
      • XERMELO (Telotristat)
      • BRINUERA(Cerliponase alfa)
      • MEPSEVII (Vestronidase)
      • PARSABIV (Etelcalcetide)
      • RADICAVA (Edaravone)
      • RHOPRESSA (Netarsudil)
    • Cardio
      • Vyndaqel (tafamidis meglumine)
    • MISC.
      • Brexafemme (Ibrexafungerp)
      • Qulipta Atogepant
      • Zemdri (Plazomicin)
      • Epidiolex (Cannabidiol)
      • ZAVICEFTA (Avibactum + Ceftazidime)
      • BAXDELA (Delafloxacin)
      • BEVYXXA (Betrixaban)
      • FASENRA (Benralizumab)
      • FIRAZYR (Icatibant)
      • KEVZARA(Sarilumab)
      • TRULANCE (Plecanatide)
      • VIVITROL (Naltrexone)
      • XADAGO (Safinamide)
      • Foscavir (Foscarnet sodium injection)
      • Anakinra (Kineret)
      • PADCEV (Enfortumab Vedotin-ejfv)
      • Lonsurf (Trifluridine/Tipiracil)
      • Dantrium IV (Dantrolene Sodium)
  • Blog
  • Contact Us

Eculizumab 300 MG Injection: Warning and Precautions

Eculizumab (Brand Name: Soliris) 300 mg is a monoclonal antibody that binds to complement protein C5 and blocks terminal complement activation. The eculizumab injection is approved to treat patients with paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome and some forms of generalized myasthenia gravis and neuromyelitis optica spectrum disorder. In patients taking treatment with this medicine, some Warnings and Precautions are recommended which should be kept in mind. These are as follows:

Severe Meningococcal Infections

Administration of eculizumab 300 mg injection typically increases a patient’s susceptibility to severe meningococcal infections (septicemia and/or meningitis). All patients without a previous history of meningococcal vaccination must receive the meningococcal vaccine at least 14 days prior to receiving the first eculizumab dose and be revaccinated as per the current medical guidelines for vaccine use. Quadrivalent, conjugate meningococcal vaccines are strongly recommended. Meningococcal infections may not be prevented by vaccination. 

Patients need to be assessed for early signs/symptoms of meningococcal infections and evaluated promptly if an infection is suspected. Health specialists should strongly consider interruption of eculizumab during the treatment of severe meningococcal infections. 

In clinical studies, 2 out of 196 PNH patients developed severe meningococcal infections while getting treatment with eculizumab; both had been vaccinated. 

Other Infections

Eculizumab blocks the terminal complement; therefore patients may have higher susceptibility to infections, mainly with encapsulated bacteria. Caution should be used when administering this medicinal product to all those patients who are with any systemic infection.

Monitoring After Eculizumab Discontinuation

Since Eculizumab (Soliris) 300 mg therapy increases the number of PNH cells, patients who discontinue treatment with soliris 300 mg may be at higher risk to have serious hemolysis. Serious hemolysis is recognised by serum LDH levels higher than the pre-treatment level, along with any of the following: higher than 25% absolute decrease in PNH clone size (in the absence of dilution because of the transfusion) in 7 days or less; a hemoglobin level of <5 gm/dL or a reduction of >4 gm/dL in 7 days or less; angina; change in mental status; a 50 percent increase in the level of serum creatinine; or thrombosis. Evaluate any patient who discontinues Eculizumab for at least 8 weeks in order to detect serious hemolysis and certain other reactions. 

In case serious hemolysis occurs following discontinuation of Eculizumab, consider the following procedures or treatments: blood transfusion (packed Red Blood Cells), or exchange transfusion if the PNH Red Blood Cells are >50 percent of the total Red Blood Cells by flow cytometry; corticosteroids; anticoagulation; or reinstitution of Eculizumab. 

In clinical studies, 16 of 196 PNH patients discontinued Eculizumab treatment. Patients were followed for findings of worsening hemolysis and no severe hemolysis was observed.

Thrombosis Prevention and Management

The effect of withdrawal of anticoagulant therapy during Eculizumab (soliris 300 mg injection) treatment has not been established. Therefore, treatment with Eculizumab should not alter the anticoagulant management. 

Laboratory Monitoring

The serum LDH quantity increases during hemolysis and may assist in monitoring the effects of Eculizumab, including the response to interruption of therapy. In clinical studies, 6 patients achieved a decrease in serum LDH quantity only after a decrease in the Eculizumab dosing interval from 14-12 days. All other patients achieved a decrease in serum LDH quantity with the 2 weeks dosing interval. 

Infusion Reactions

As with all existing protein products, administration of Eculizumab may result in some infusion reactions, including anaphylaxis or other hypersensitivity reactions. In clinical trials, no PNH patients experienced an infusion reaction which required discontinuation of Eculizumab. The administration of Eculizumab should be interrupted in all patients experiencing severe infusion reactions and apt medical therapy administered.

 
 General Information About Eculizumab 

Eculizumab is a composition of Soliris. It is a solution of water, sodium phosphate, polysorbate, and sodium chloride. In case you have any concerns about SOLIRIS (ECULIZUMAB INJECTION), DOSAGE, AND SIDE EFFECTS, ask your health specialist. 
 
Price of Eculizumab: Eculizumab is a FDA-approved and a prescription medicine named a monoclonal antibody. The price of eculizumab in India is very reasonable and might vary on behalf of availability of different types of brands. Please contact +91-9310090915 | TOLL-FREE Number: 1800-889-1064 for eculizumab price in India.
  • Posted by admin
  • On May 5, 2022
  • 0 Comments
  • 0 likes
Tags: eculizumab 10 mg, eculizumab cost, eculizumab injection, eculizumab price in india, pnh treatment, soliris cost, soliris injection price in india, soliris price

0 Comments

Leave Reply Cancel reply

You must be logged in to post a comment.

Archives
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
Categories
  • Achondroplasia (1)
  • acute lymphocytic leukemia (4)
  • Adrenal Cancer (1)
  • adrenal gland (1)
  • Bladder Cancer (3)
  • blood cancer (2)
  • Breast Cancer (9)
  • Chronic Lymphocytic Leukemia (2)
  • CMV (1)
  • Crohn’s disease (1)
  • DLBCL (1)
  • Drug & Cosmetic Act (1)
  • Enhertu (2)
  • hereditary tyrosinemia (1)
  • Hodgkin Lymphoma (4)
  • leukaemia (2)
  • Metastatic Breast Cancer (3)
  • metastatic colorectal cancer (2)
  • name patient import (1)
  • named patient program india (2)
  • NSCLC (1)
  • PNH (2)
  • RETEVMO (1)
  • rheumatoid arthritis (1)
  • Stomach Gastric Cancer (1)
  • T-cell Acute Lymphoblastic Leukaemia (1)
  • thyroid carcinoma (2)
  • Uncategorized (1)
Archives
  • March 2023
  • February 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • February 2022
  • January 2022
  • December 2021
  • October 2021
Popular Posts
  • Understanding Rheumatoid Arthritis (RA)December 20, 2021
  • Nelarabine : Drug Information for PatientsOctober 29, 2021
  • Blincyto Treatment for Acute Lymphoblastic LeukemiaDecember 3, 2021
Photo Stream

Nelarabine : Drug Information for Patients

Previous thumb

Hodgkin's Lymphoma Treatment

Next thumb
Scroll

Indian Pharma Network helps in accessing new products in India. These products are launched and approved recently in USA or Europe but yet to be approved in India. We help in accessing these new launches through named patient import.

Quick Links
  • Home
  • About Us
  • Blog
  • Contact us
About Us

Indian Pharma Network facilitates patients connecting with genuine pharmaceutical suppliers, wholesalers and dealers.

Indian Pharma Network.
info@indianpharmanetwork.in
Corporate Office
Indian Pharma Network.
905 – 9th Floor, I-Thum Business Park,
Tower A, Plot no. A-40, Unit no. 5,
Sector-62, Noida 201301,
info@indianpharmanetwork.in
  • +91 9310090915

  • @2022 All Right Reserved indianpharmanetwork

    WhatsApp us

    • Home
    • About Us
    • Product List
      • ONCOLOGY
        • Cytalux (Pofalacianine)
        • Pylarify (Piflufolastat F18)
        • Truseltiq (Infigratinib)
        • Enhertu (Trastuzumab Deruxtecan)
        • Mektovi (Binimetinib)
        • Braftovi (Encorafenib)
        • Libtayo (Cemiplimab-rwlc)
        • Lorbrena (Lorlatinib)
        • Talzenna (Talazoparib)
        • Balversa (Erdafitinib)
        • Piqray (Alpelisib)
        • Alunbrig (Brigatinib)
        • Jemperli (Dostarlimab-gxly)
        • Tepmetko (Tepotinib)
        • COSELA (Trilaciclib)
        • Fotivda (Tivozanib)
        • Rozlytrek (Entrectinib)
        • Tivdak® (tisotumab vedotin-tftv)
        • Ayvakit (Avapritinib)
        • Tazverik (Tazemetostat)
        • Tukysa (Tucatinib)
        • Pemazyre (Pemigatinib)
        • Trodelvy (Sacituzumab govitecan-hziy)
        • Tabrecta (Capmatinib)
        • Retevmo (Selpercatinib)
        • Zepzelca (Lurbinectedin)
        • Gavreto (Pralsetinib)
        • MARGENZATM (margetuximab-cmkb)
        • Orgovyx (relugolix)
        • DANYELZA (naxitamab-gqgk)
        • ZEJULA (Niraparib)
        • VERZENIO (Abemaciclib)
        • TECENTRIQ (Atezolizumab)
        • NERLYNX (Neratinib)
        • Yervoy
        • CAPRELSA (Vandetnib)
        • CELSENTRI (Maraviroc)
        • CIDOFOVIR (Visitide)
        • IBRANCE (Palbociclib Capsules)
        • COMETRIQ (Cabozantinib)
        • CYRAMZA (Ramucirumab Injection)
        • DABRAFENIB (Tafinlar)
        • ENTEREG (Almiopan Capsule)
        • ERIVEDGE (Vismodegib Tablet)
        • LYNPARZA (Olaparib)
        • Qinlock (Ripretinib)
        • MEKINIST (Trametnib Tablet)
        • Mitotane (Lysodren)
        • NAVELBINE ORAL (Vinorelbine)
        • TEYSUNO (Tegafur)
        • ZELBORAF (Vemurafenib Tablet)
        • Zepzelca (Lurbinectedin)
        • ZYDELIG (Idelalisib)
      • HEMATOLOGY
        • Rezurock (Belumosudil)
        • Empaveli (Pegcetacoplan)
        • Idhifa (Enasidenib)
        • Besponsa (Inotuzumab Ozogamicin)
        • Tibsovo (Ivosidenib)
        • Poteligeo (Mogamulizumab-kpkc)
        • Xospata (Gilteritinib)
        • Asparlas (Calaspargase pegol-mknl)
        • Polivy (Polatuzumab Vedotin-piiqa
        • Reblozyl (Luspatercept–aamt)
        • Ukoniq (Umbralisib)
        • Pepaxto (Melphalan Flufenamide)
        • Zynlonta (Loncastuximab Tesirine-lpyl)
        • Rylaze
        • Exkivity (Mobocertinib)
        • SCEMBLIX®(Asciminib)
        • Besremi (Ropeginterferon alfa-2b-njft)
        • SARCLISA® (isatuximab-irfc)
        • Inqovi (decitabine and cedazuridine)
        • Blenrep (Belantamab Mafodotin-blmf)
        • Monjuvi (Tafasitamab-cxix)
        • TAFINLAR (Dabrafenib)
        • CALQUENCE (Acalabrutinib)
        • MYLOTARG Gemtuzumab
        • Aliqopa(Copanlisib)
        • Brentuximab Vedotin
        • AGRYLIN (Anagrelide Hydrochloride)
        • ATRIANCE (Nelarabine)
        • BLINCYTO (Blinatumomab)
        • ONCASPAR (Pegaspargase)
        • ERWINAZE (Asparaginase Erwinia Chrysanthemi)
        • FOLOTYN (Pralatrexate)
        • TREOSULFAN (Treosulfan)
        • Ponatinib
        • NPLATE (Romiplostim)
        • KYPROLIS (Carfilzomib)
        • MABCAMPATH (Alemtuzumab)
        • VENCLEXTA (Venetoclax)
        • SOLIRIS (eculizumab)
        • SYNRIBO (Omacetaxine Mepesuccinate)
        • ALKERAN (Melphalan)
        • FARYDAK (Panobinostat)
        • BOSULIF (Bosutinib)
        • ELDISINE (Vindesine Sulphate)
        • Ixazomib Citrate
        • TEPADINA (Thiotepa)
        • ZOLINZA (Vorinostat)
      • Nephrology
        • Ultomiris (Ravulizumab)
      • GASTROENTROLOGY
        • VOSEVI (Sofosbuvir, Velpatasvir, And Voxilaprevir)
        • OLYSIO (SIMEPREVIR)
        • SYPRINE (Trientine HCL)
      • NEUROLOGY
        • Azstarys (Serdexmethylphenidate and Dexmethylphenidate)
        • Qelbree (Viloxazine)
        • Lybalvi (Olanzapine and Samidorphan)
        • Aduhelm (aducanumab-avwa)
        • NUEDEXTA (Dextromethorphan Hydrobromide)
        • ILARIS (Canakinumab)
        • GLIOLAN (Aminolevulinic acid hydrochloride)
        • STELARA (Ustekinumab)
        • HUMIRA (Adalimumab)
      • IMMUNOLOGY
        • Ocrevus (Ocrelizumab)
        • Skyrizi (Risankizumab-rzaa)
        • PONVORY®(ponesimod)
        • Zeposia (Ozanimod)
        • SILIQ (Brodalumab)
        • TREMFYA (Guselkumab)
      • RARE DISEASES
        • Nulibry (Fosdenopterin)
        • Welireg (Belzutifan)
        • Xiaflex (Collagenase Clostridium Histolyticum)
        • Mepsevii (Vestronidase alfa-vjbk)
        • Symdeko (Tezacaftor/Ivacaftor & Ivacaftor)
        • Palynziq (Pegvaliase-pqpz)
        • Onpattro (Patisiran)
        • Galafold (Migalastat)
        • Diacomit (Stiripentol)
        • Takhzyro (Lanadelumab)
        • Orfadin (Nitisinone)
        • Trikafta (elexacaftor, tezacaftor and ivacaftor)
        • Spinraza (Nusinersen)
        • Amondys 45 (Casimersen)
        • Voxzogo (Vosoritide)
        • Tepezza (Teprotumumab-trbw)
        • Isturisa (Osilodrostat)
        • Koselugo (Selumetinib)
        • VILTEPSO (Viltolarsen)
        • XERMELO (Telotristat)
        • BRINUERA(Cerliponase alfa)
        • MEPSEVII (Vestronidase)
        • PARSABIV (Etelcalcetide)
        • RADICAVA (Edaravone)
        • RHOPRESSA (Netarsudil)
      • Cardio
        • Vyndaqel (tafamidis meglumine)
      • MISC.
        • Brexafemme (Ibrexafungerp)
        • Qulipta Atogepant
        • Zemdri (Plazomicin)
        • Epidiolex (Cannabidiol)
        • ZAVICEFTA (Avibactum + Ceftazidime)
        • BAXDELA (Delafloxacin)
        • BEVYXXA (Betrixaban)
        • FASENRA (Benralizumab)
        • FIRAZYR (Icatibant)
        • KEVZARA(Sarilumab)
        • TRULANCE (Plecanatide)
        • VIVITROL (Naltrexone)
        • XADAGO (Safinamide)
        • Foscavir (Foscarnet sodium injection)
        • Anakinra (Kineret)
        • PADCEV (Enfortumab Vedotin-ejfv)
        • Lonsurf (Trifluridine/Tipiracil)
        • Dantrium IV (Dantrolene Sodium)
    • Blog
    • Contact Us